DCR

malignant mesothelioma (mMS) - 1st line (L1) malignant mesothelioma (mMS) - 1st line (L1)

malignant mesothelioma (mMS) - 2nd line (L2) malignant mesothelioma (mMS) - 2nd line (L2)

versus placebo
tremelimumab vs. placebo 1 certainty unassessable+39%